NUCYNTA®: TITRATE TO AN OPTIMAL THERAPEUTIC DOSE1

NUCYNTA® is available in 50 mg, 75 mg, and 100 mg doses for titration to a therapeutic dose

Initiate, Titrate, Maintain

 

Tablets shown not actual size

 

CONVERSION FROM NUCYNTA® TO NUCYNTA® ER (TAPENTADOL) EXTENDED-RELEASE TABLETS, CII2

  • Patients can be converted from NUCYNTA® to NUCYNTA® ER using the equivalent total daily dose of NUCYNTA® and dividing it into 2 equal doses, separated by ~12-hour intervals*
  • Although the maximum approved total daily dose of immediate-release NUCYNTA® is 600 mg per day (700 mg on the first day of therapy), the maximum total daily dose of NUCYNTA® ER is 500 mg

NUCYNTA® ER must be swallowed whole, with or without food.

*There are no established conversion ratios from other opioids to NUCYNTA® ER defined by clinical trials.

DOSAGE AND ADMINISTRATION:

Continual re-evaluation of the patient receiving tapentadol is important, with special attention to the maintenance of pain control and the relative incidence of side effects associated with therapy. During chronic therapy, especially for non-cancer-related pain, periodically re-assess the continued need for the use of opioid analgesics. Please see full Prescribing Information for complete information on DOSAGE AND ADMINISTRATION.

References
  1. NUCYNTA® (package insert). Titusville, NJ: Janssen Pharmaceuticals, Inc; 2009.
  2. NUCYNTA® ER (package insert). Titusville, NJ: Janssen Pharmaceuticals, Inc; 2014.